Buspirone for the Treatment of Chronic Post-TBI Irritability and Aggression: A 91-Day Single-Site, Flexible-Dose, Parallel Group, Randomized, Placebo-Controlled Trial

Project Type
Independent
Principal Investigator Name
Flora Hammond, M.D.
Principal Investigator Email
Start Date:
10/1/2012
End Date:
9/30/2017
Participating Centers:
Target Population(s):
Project Website:
Abstract:
A prospective randomized placebo controlled trial off the efficacy of buspirone in treating post-TBI irritability or aggression. Buspirone, sold under the brand names Buspar and Vanspar, is primarily prescribed to treat anxiety disorders or short-term symptoms of anxiety and has not been specifically evaluated for treating irritability or aggression after TBI.